185 related articles for article (PubMed ID: 27234586)
21. Lonidamine in the combined treatment of malignant gliomas. A randomized study.
Carapella CM; Paggi MG; Calvosa F; Cattani F; Jandolo B; Mastrostefano R; Raus L; Riccio A
J Neurosurg Sci; 1990; 34(3-4):261-4. PubMed ID: 2098504
[TBL] [Abstract][Full Text] [Related]
22. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.
Floridi A; Paggi MG; Marcante ML; Silvestrini B; Caputo A; De Martino C
J Natl Cancer Inst; 1981 Mar; 66(3):497-9. PubMed ID: 6937706
[TBL] [Abstract][Full Text] [Related]
23. [Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line].
Fuchs AG
Medicina (B Aires); 2008; 68(1):13-22. PubMed ID: 18416315
[TBL] [Abstract][Full Text] [Related]
24. Phase I toxicologic study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():56-9. PubMed ID: 6717896
[TBL] [Abstract][Full Text] [Related]
25. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437.
Belzacq AS; El Hamel C; Vieira HL; Cohen I; Haouzi D; Métivier D; Marchetti P; Brenner C; Kroemer G
Oncogene; 2001 Nov; 20(52):7579-87. PubMed ID: 11753636
[TBL] [Abstract][Full Text] [Related]
26. Cell membrane changes induced by lonidamine in human erythrocytes and T lymphocytes, and Ehrlich ascites tumor cells.
De Martino C; Malorni W; Accinni L; Rosati F; Nista A; Formisano G; Silvestrini B; Arancia G
Exp Mol Pathol; 1987 Feb; 46(1):15-30. PubMed ID: 3492392
[TBL] [Abstract][Full Text] [Related]
27. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters.
Marchiq I; Pouysségur J
J Mol Med (Berl); 2016 Feb; 94(2):155-71. PubMed ID: 26099350
[TBL] [Abstract][Full Text] [Related]
29. Lonidamine can enhance the cytotoxic effect of cisplatin in human tumour cells and rodent cells.
Raaphorst GP; Feeley MM; Heller DP; Danjoux CE; Martin L; Maroun JA; De Sanctis AJ
Anticancer Res; 1990; 10(4):923-7. PubMed ID: 2382989
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of radiation effects on two murine tumors by lonidamine.
Kim JH; Alfieri AA; Kim SH; Young CW
Cancer Res; 1986 Mar; 46(3):1120-3. PubMed ID: 3943089
[TBL] [Abstract][Full Text] [Related]
31. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
32. Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.
Krasnov GS; Dmitriev AA; Lakunina VA; Kirpiy AA; Kudryavtseva AV
Expert Opin Ther Targets; 2013 Oct; 17(10):1221-33. PubMed ID: 23984984
[TBL] [Abstract][Full Text] [Related]
33. The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1.
Chambers JW; Fowler ML; Morris MT; Morris JC
Mol Biochem Parasitol; 2008 Apr; 158(2):202-7. PubMed ID: 18262292
[TBL] [Abstract][Full Text] [Related]
34. The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment.
Huang Y; Sun G; Sun X; Li F; Zhao L; Zhong R; Peng Y
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33187214
[TBL] [Abstract][Full Text] [Related]
35. Lonidamine: an innovative therapy in oncology.
Semin Oncol; 1991 Apr; 18(2 Suppl 4):1-72. PubMed ID: 2031190
[No Abstract] [Full Text] [Related]
36. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Band PR; Maroun J; Pritchard K; Stewart D; Coppin CM; Wilson K; Eisenhauer EA
Cancer Treat Rep; 1986 Nov; 70(11):1305-10. PubMed ID: 3768873
[TBL] [Abstract][Full Text] [Related]
37. Effect of lonidamine on the mitochondrial potential in situ in Ehrlich ascites tumor cells.
Pulselli R; Amadio L; Fanciulli M; Floridi A
Anticancer Res; 1996; 16(1):419-23. PubMed ID: 8615647
[TBL] [Abstract][Full Text] [Related]
38. Modification of tumor cell sensitivity to antineoplastic agents lonidamine and bouvardin (NSC 259968) at elevated temperatures.
Adwankar MK; Chitnis MP
Neoplasma; 1986; 33(2):217-23. PubMed ID: 3713924
[TBL] [Abstract][Full Text] [Related]
39. Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.
Young CW; Currie VE; Kim JH; O'Hehir MA; Farag FM; Kinahan JE
Oncology; 1984; 41 Suppl 1():60-5. PubMed ID: 6717897
[TBL] [Abstract][Full Text] [Related]
40. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore.
Ravagnan L; Marzo I; Costantini P; Susin SA; Zamzami N; Petit PX; Hirsch F; Goulbern M; Poupon MF; Miccoli L; Xie Z; Reed JC; Kroemer G
Oncogene; 1999 Apr; 18(16):2537-46. PubMed ID: 10353597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
